ALKERMES PLC
NASDAQ: ALKS (Alkermes plc)
Last update: 4 minutes ago46.14
0.03 (0.08%)
| Previous Close | 46.10 |
| Volume | 333,044 |
| Price / Earnings (Forward) | 133.33 |
| Price / Sales | 4.72 |
| Price / Book | 4.35 |
| 52 Weeks Range |
| Profit Margin | 23.30% |
| Operating Margin (TTM) | 4.50% |
| Diluted EPS (TTM) | 2.10 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Quarterly Earnings Growth (YOY) | -39.00% |
| Total Debt/Equity (MRQ) | 4.90% |
| Current Ratio (MRQ) | 3.33 |
| Operating Cash Flow (TTM) | 516.83 M |
| Levered Free Cash Flow (TTM) | 429.53 M |
| Return on Assets (TTM) | 11.62% |
| Return on Equity (TTM) | 25.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Alkermes plc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | -1.70 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.49% |
| % Held by Institutions | 107.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 10,012,267 |
| Vanguard Portfolio Management Llc | 30 Jun 2026 | 9,490,818 |
| Price T Rowe Associates Inc /Md/ | 30 Jun 2026 | 6,737,328 |
| Renaissance Technologies Llc | 30 Jun 2026 | 6,460,928 |
| Deep Track Capital, Lp | 30 Jun 2026 | 4,000,000 |
| Holocene Advisors, Lp | 30 Jun 2026 | 3,601,472 |
| Commodore Capital Lp | 30 Jun 2026 | 3,000,000 |
| Wellington Management Group Llp | 30 Jun 2026 | 2,814,804 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GAFFIN DAVID JOSEPH | - | 46.88 | -2,034 | -95,354 |
| HOPKINSON CRAIG C. | - | 47.20 | -9,000 | -424,800 |
| Aggregate Net Quantity | -11,034 | |||
| Aggregate Net Value ($) | -520,154 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 47.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GAFFIN DAVID JOSEPH | Officer | 03 Sep 2026 | Automatic sell (-) | 2,034 | 46.88 | 95,354 |
| HOPKINSON CRAIG C. | Officer | 01 Sep 2026 | Automatic sell (-) | 9,000 | 47.20 | 424,800 |
| HOPKINSON CRAIG C. | Officer | 01 Sep 2026 | Option execute | 5,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |